Faricimab Fixed Quarterly Maintenance for Neovascular Age Related Macular Degeneration: A Prospective Case Series
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
We aimed to investigate the success rate of a planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab, for nAMD to achieve stability without recurrence at a tertiary eye centre.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Healthy Volunteers: f
View:
• Subjects aged over 50 years, neovascular AMD with foveal involvement, both treatment-naïve and recurrent cases. There were no specific criteria for initial best-corrected visual acuity (BCVA). Only active subfoveal MNV are included, including types 1, 2, and 3.
Locations
Other Locations
Hong Kong Special Administrative Region
Department of Ophthalmology, United Chrisitian Hospital
RECRUITING
Hong Kong
Contact Information
Primary
Daniel Ho Tak Wong, FRCOphth (UK)
WHT454@ha.org.hk
+852 3949 3411
Time Frame
Start Date: 2025-08-21
Estimated Completion Date: 2027-02-01
Participants
Target number of participants: 40
Treatments
Active_comparator: Faricimab treatment arm
A planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab. The intervention faricimab is injected into the eyeball with a 30G needle.
Related Therapeutic Areas
Sponsors
Leads: Hospital Authority, Hong Kong